Moderna, Inc. (MRNA) key performance indicators and operating metrics (66 metrics) from SEC EDGAR filings, earnings calls, and investor decks. First-party data.
| Metric | Latest Value | Period |
|---|---|---|
| R&D expenses | 649M | FY2026-Q1 |
| SG&A expenses | 173M | FY2026-Q1 |
| Cash, cash equivalents and investments | 7.5B | FY2026-Q1 |
| Loss per share – Basic and Diluted | -3.40 USD_per_share | FY2026-Q1 |
| Cash & investments | 7.5B | FY2026-Q1 |
| Cost of sales (GAAP) | 955M | FY2026-Q1 |
| Other income, net | 54B | FY2026-Q1 |
| Revenue - U.S. | 300M | FY2025-Q4 |
| Effective tax rate | -3.00 percent | FY2025-Q4 |
| Product sales (U.S.) | 264M | FY2025-Q4 |
| Selling, general & administrative (SG&A) expenses | 308M | FY2025-Q4 |
| Weighted average shares – Basic and Diluted | 392B | FY2025-Q4 |
| Loss per share | 2.11 USD_per_share | FY2025-Q4 |
| Moderna Total revenue | 1.02T | FY2025-Q3 |
Back to MRNA overview · MRNA earnings · MRNA holders
Data sourced from U.S. SEC EDGAR filings, earnings call transcripts, and investor decks. Not personalized investment advice.